Compare PPTA & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPTA | SUPN |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.0B |
| IPO Year | 2011 | 2010 |
| Metric | PPTA | SUPN |
|---|---|---|
| Price | $25.21 | $48.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $37.38 | ★ $61.60 |
| AVG Volume (30 Days) | ★ 1.3M | 659.2K |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $392,755,000.00 |
| Revenue This Year | N/A | $22.70 |
| Revenue Next Year | N/A | $19.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.68 | $31.16 |
| 52 Week High | $37.37 | $59.68 |
| Indicator | PPTA | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 40.31 | 44.90 |
| Support Level | $24.98 | $47.73 |
| Resistance Level | $25.97 | $52.36 |
| Average True Range (ATR) | 2.01 | 2.21 |
| MACD | -0.42 | -0.15 |
| Stochastic Oscillator | 8.29 | 26.76 |
Perpetua Resources Corp is engaged in acquiring mining properties with the intention of exploring, evaluating, developing and placing them into production, if warranted. Its principal mineral project is the Stibnite Gold Project in Idaho, USA, which contains several gold, silver and antimony mineral deposits. The company's current focus is to redevelop three of the Deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project, as well as reprocess certain historical tailings located on the Project. It operates in one segment: mineral exploration and development in the United States.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.